Advertisement

Correlates of Vaccine-Induced Immunity: Historical Perspectives and Future Challenges

  • Ian J. AmannaEmail author
Chapter

Abstract

Despite the broad diversity of vaccines available for use in humans, the majority of licensed vaccines utilize serum antibody responses as the primary correlate of protection. However, the immunity afforded from such protective thresholds may vary from near absolute defense, to something as weak as a simple surrogate measure with little direct role in preventing disease. Understanding the historical context in which immune correlates have been defined can better inform future vaccines, even as vaccine development begins to explore the computational power of systems biology approaches and next generation vaccine technologies.

Keywords

Vaccine correlates Humoral immunity Cellular immunity 

References

  1. Amanna I, Slifka MK (2005) Public fear of vaccination: separating fact from fiction. Viral Immunol 18:307–315PubMedCrossRefGoogle Scholar
  2. Amanna IJ, Slifka MK (2009) Wanted, dead or alive: new viral vaccines. Antiviral Res 84:119–130PubMedCrossRefGoogle Scholar
  3. Amanna IJ, Carlson NE, Slifka MK (2007) Duration of humoral immunity to common viral and vaccine antigens. N Engl J Med 357:1903–1915PubMedCrossRefGoogle Scholar
  4. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H (1998) Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. Am J Prev Med 15:1–8PubMedCrossRefGoogle Scholar
  5. Baba K, Yabuuchi H, Okuni H, Takahashi M (1978) Studies with live varicella vaccine and inactivated skin test antigen: protective effect of the vaccine and clinical application of the skin test. Pediatrics 61:550–555PubMedGoogle Scholar
  6. Beecher HK (1966) Ethics and clinical research. N Engl J Med 274:1354–1360PubMedCrossRefGoogle Scholar
  7. Bernstein A, Pulendran B, Rappuoli R (2011) Systems vaccinomics: the road ahead for vaccinology. OMICS 15:529–531PubMedCrossRefGoogle Scholar
  8. Bin D, Zhihui C, Qichang L, Ting W, Chengyin G, Xingzi W, Hanhau F, Yongzhong X (1991) Duration of immunity following immunization with live measles vaccine: 15 years of observation in Zhejiang Province, China. Bull World Health Organ 69:415–423Google Scholar
  9. Bruton OC (1952) Agammaglobulinemia. Pediatrics 9:722–728PubMedGoogle Scholar
  10. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, Gilbert PB, Lama JR, Marmor M, Del Rio C, McElrath MJ, Casimiro DR, Gottesdiener KM, Chodakewitz JA, Corey L, Robertson MN (2008) Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372:1881–1893PubMedCrossRefGoogle Scholar
  11. CDC (2011a) Measles. In: Atkinson W, Wolfe S, Hamborsky J (eds) Epidemiology and prevention of vaccine-preventable diseases, 12th edn. Public Health Foundation, Washington, DCGoogle Scholar
  12. CDC (2011b) Summary of notifiable diseases: United States, 2009. MMWR Morb Mortal Wkly Rep 58:1–100Google Scholar
  13. CDC (2011c) Tetanus. In: Atkinson W, Wolfe S, Hamborsky J (eds) Epidemiology and prevention of vaccine-preventable diseases, 12th edn. Public Health Foundation, Washington, DCGoogle Scholar
  14. CDC (2011d) Varicella. In: Atkinson W, Wolfe S, Hamborsky J (eds) Epidemiology and prevention of vaccine-preventable diseases, 12th edn. Public Health Foundation, Washington, DCGoogle Scholar
  15. Chan IS, Li S, Matthews H, Chan C, Vessey R, Sadoff J, Heyse J (2002) Use of statistical models for evaluating antibody response as a correlate of protection against varicella. Stat Med 21:3411–3430PubMedCrossRefGoogle Scholar
  16. Chaves SS, Gargiullo P, Zhang JX, Civen R, Guris D, Mascola L, Seward JF (2007) Loss of vaccine-induced immunity to varicella over time. N Engl J Med 356:1121–1129PubMedCrossRefGoogle Scholar
  17. Chen RT, Markowitz LE, Albrecht P, Stewart JA, Mofenson LM, Preblud SR, Orenstein WA (1990) Measles antibody: reevaluation of protective titers. J Infect Dis 162:1036–1042PubMedCrossRefGoogle Scholar
  18. Christie AS, Gay A (2011) The Measles Initiative: moving toward measles eradication. J Infect Dis 204(Suppl 1):S14–S17PubMedCrossRefGoogle Scholar
  19. Committee on Infectious Disease (2007) Prevention of varicella: recommendations for use of varicella vaccines in children, including a recommendation for a routine 2-dose varicella immunization schedule. Pediatrics 120:221–231CrossRefGoogle Scholar
  20. Crotty S, Felgner P, Davies H, Glidewell J, Villareal L, Ahmed R (2003) Cutting edge: long-term B cell memory in humans after smallpox vaccination. J Immunol 171:4969–4973PubMedGoogle Scholar
  21. Cutts FT (1996) The immunological basis for immunization series. Module 7: measles. WHO Global Programme for Vaccines and Immunization, GenevaGoogle Scholar
  22. D’Argenio DA, Wilson CB (2010) A decade of vaccines: integrating immunology and vaccinology for rational vaccine design. Immunity 33:437–440PubMedCrossRefGoogle Scholar
  23. D’Souza MP, Altfeld M (2008) Measuring HIV-1-specific T cell immunity: how valid are current assays? J Infect Dis 197:337–339PubMedCrossRefGoogle Scholar
  24. Dienstag JL, Werner BG, Polk BF, Snydman DR, Craven DE, Platt R, Crumpacker CS, Ouellet-Hellstrom R, Grady GF (1984) Hepatitis B vaccine in health care personnel: safety, immunogenicity, and indicators of efficacy. Ann Intern Med 101:34–40PubMedGoogle Scholar
  25. Douglas RG, Sadoff J, Samant V (2008) The vaccine industry. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 5th edn. Saunders/Elsevier, PhiladelphiaGoogle Scholar
  26. Fine P, Eames K, Heymann DL (2011) “Herd immunity”: a rough guide. Clin Infect Dis 52:911–916PubMedCrossRefGoogle Scholar
  27. Francis DP, Hadler SC, Thompson SE, Maynard JE, Ostrow DG, Altman N, Braff EH, O’Malley P, Hawkins D, Judson FN, Penley K, Nylund T, Christie G, Meyers F, Moore JN Jr, Gardner A, Doto IL, Miller JH, Reynolds GH, Murphy BL, Schable CA, Clark BT, Curran JW, Redeker AG (1982) The prevention of hepatitis B with vaccine. Report of the centers for disease control multi-center efficacy trial among homosexual men. Ann Intern Med 97:362–366PubMedGoogle Scholar
  28. Galazka A (1993) The immunological basis for immunization series. Module 3: tetanus. World Health Organization, GenevaGoogle Scholar
  29. Gill DM (1982) Bacterial toxins: a table of lethal amounts. Microbiol Rev 46:86–94PubMedGoogle Scholar
  30. GlaxoSmithKline Biologicals (2010) Engerix-B® package insert, December edn. GlaxoSmithKline Biologicals, Research Triangle ParkGoogle Scholar
  31. Good RA, Zak SJ (1956) Disturbances in gamma globulin synthesis as experiments of nature. Pediatrics 18:109–149PubMedGoogle Scholar
  32. Goulon M, Girard O, Grosbuis S, Desormeau JP, Capponi MF (1972) Antitetanus antibodies. Assay before anatoxinotherapy in 64 tetanus patients. Nouv Presse Med 1:3049–3050PubMedGoogle Scholar
  33. Hambleton S, Gershon AA (2005) Preventing varicella-zoster disease. Clin Microbiol Rev 18:70–80PubMedCrossRefGoogle Scholar
  34. Hammarlund E, Lewis MW, Hansen SG, Strelow LI, Nelson JA, Sexton GJ, Hanifin JM, Slifka MK (2003) Duration of antiviral immunity after smallpox vaccination. Nat Med 9:1131–1137PubMedCrossRefGoogle Scholar
  35. Hammond O, Wang Y, Green T, Antonello J, Kuhn R, Motley C, Stump P, Rich B, Chirmule N, Marchese RD (2006) The optimization and validation of the glycoprotein ELISA assay for quantitative varicella-zoster virus (VZV) antibody detection. J Med Virol 78:1679–1687PubMedCrossRefGoogle Scholar
  36. Hansen SG, Ford JC, Lewis MS, Ventura AB, Hughes CM, Coyne-Johnson L, Whizin N, Oswald K, Shoemaker R, Swanson T, Legasse AW, Chiuchiolo MJ, Parks CL, Axthelm MK, Nelson JA, Jarvis MA, Piatak M Jr, Lifson JD, Picker LJ (2011) Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473:523–527PubMedCrossRefGoogle Scholar
  37. Haralambieva IH, Ovsyannikova IG, O’Byrne M, Pankratz VS, Jacobson RM, Poland GA (2011) A large observational study to concurrently assess persistence of measles specific B-cell and T-cell immunity in individuals following two doses of MMR vaccine. Vaccine 29:4485–4491PubMedCrossRefGoogle Scholar
  38. Horowitz MM, Ershler WB, McKinney WP, Battiola RJ (1988) Duration of immunity after hepatitis B vaccination: efficacy of low-dose booster vaccine. Ann Intern Med 108:185–189PubMedGoogle Scholar
  39. Ipsen J (1946) Circulating antitoxin at the onset of diphtheria in 425 patients. J Immunol 54:325–327PubMedGoogle Scholar
  40. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC (1999) What level of hepatitis B antibody is protective? J Infect Dis 179:489–492PubMedCrossRefGoogle Scholar
  41. Janeway C (1945) Use of concentrated human serum γ-globulin in the prevention and attenuation of measles. Bull N Y Acad Med 21:202–222PubMedGoogle Scholar
  42. Kamiya H, Ihara T, Hattori A, Iwasa T, Sakurai M, Izawa T, Yamada A, Takahashi M (1977) Diagnostic skin test reactions with varicella virus antigen and clinical application of the test. J Infect Dis 136:784–788PubMedCrossRefGoogle Scholar
  43. Kane M, Banatvala J, Da Villa G, Esteban R, Franco E, Goudeau A, Grob P, Jilg W, Rizzetto M, Van Damme P, Van Hattum J, West D, Zuckerman J (2000) Are booster immunisations needed for lifelong hepatitis B immunity? Lancet 355:561–565CrossRefGoogle Scholar
  44. Keating GM, Noble S (2003) Recombinant hepatitis B vaccine (Engerix-B): a review of its immunogenicity and protective efficacy against hepatitis B. Drugs 63:1021–1051PubMedCrossRefGoogle Scholar
  45. Keller MA, Stiehm ER (2000) Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev 13:602–614PubMedCrossRefGoogle Scholar
  46. Koup RA, Graham BS, Douek DC (2011) The quest for a T cell-based immune correlate of protection against HIV: a story of trials and errors. Nat Rev Immunol 11:65–70PubMedCrossRefGoogle Scholar
  47. Krugman S (1986) The Willowbrook hepatitis studies revisited: ethical aspects. Rev Infect Dis 8:157–162PubMedCrossRefGoogle Scholar
  48. Krugman S, Ward R (1958) Clinical and experimental studies of infectious hepatitis. Pediatrics 22:1016–1022PubMedGoogle Scholar
  49. Krugman S, Giles JP, Hammond J (1971) Viral hepatitis, type B (MS-2 strain). Studies on active immunization. JAMA 217:41–45PubMedCrossRefGoogle Scholar
  50. Kuter B, Matthews H, Shinefield H, Black S, Dennehy P, Watson B, Reisinger K, Kim LL, Lupinacci L, Hartzel J, Chan I (2004) Ten year follow-up of healthy children who received one or two injections of varicella vaccine. Pediatr Infect Dis J 23:132–137PubMedCrossRefGoogle Scholar
  51. Lee MS, Nokes DJ, Hsu HM, Lu CF (2000) Protective titres of measles neutralising antibody. J Med Virol 62:511–517PubMedCrossRefGoogle Scholar
  52. Li S, Chan IS, Matthews H, Heyse JF, Chan CY, Kuter BJ, Kaplan KM, Vessey SJ, Sadoff JC (2002) Inverse relationship between six week postvaccination varicella antibody response to vaccine and likelihood of long term breakthrough infection. Pediatr Infect Dis J 21:337–342PubMedCrossRefGoogle Scholar
  53. McComb JA (1964) The prophylactic dose of homologous tetanus antitoxin. N Engl J Med 270:175–178PubMedCrossRefGoogle Scholar
  54. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, Defawe OD, Carter DK, Hural J, Akondy R, Buchbinder SP, Robertson MN, Mehrotra DV, Self SG, Corey L, Shiver JW, Casimiro DR (2008) HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372:1894–1905PubMedCrossRefGoogle Scholar
  55. McMahon BJ, Bruden DL, Petersen KM, Bulkow LR, Parkinson AJ, Nainan O, Khristova M, Zanis C, Peters H, Margolis HS (2005) Antibody levels and protection after hepatitis B vaccination: results of a 15-year follow-up. Ann Intern Med 142:333–341PubMedGoogle Scholar
  56. Merck & Co (2010) Recombivax HB® package insert, December edn. Merck & Co., Whitehouse StationGoogle Scholar
  57. Merck & Co (2011) Varivax® package insert, April edn. Merck & Co., Whitehouse StationGoogle Scholar
  58. Nahmias AJ, Griffith D, Salsbury C, Yoshida K (1967) Thymic aplasia with lymphopenia, plasma cells, and normal immunoglobulins. Relation to measles virus infection. JAMA 201:729–734PubMedCrossRefGoogle Scholar
  59. Nakaya HI, Wrammert J, Lee EK, Racioppi L, Marie-Kunze S, Haining WN, Means AR, Kasturi SP, Khan N, Li GM, McCausland M, Kanchan V, Kokko KE, Li S, Elbein R, Mehta AK, Aderem A, Subbarao K, Ahmed R, Pulendran B (2011) Systems biology of vaccination for seasonal influenza in humans. Nat Immunol 12:786–795PubMedCrossRefGoogle Scholar
  60. Nguyen HQ, Jumaan AO, Seward JF (2005) Decline in mortality due to varicella after implementation of varicella vaccination in the United States. N Engl J Med 352:450–458PubMedCrossRefGoogle Scholar
  61. Oxman MN, Levin MJ, Johnson GR, Schmader KE, Straus SE, Gelb LD, Arbeit RD, Simberkoff MS, Gershon AA, Davis LE, Weinberg A, Boardman KD, Williams HM, Zhang JH, Peduzzi PN, Beisel CE, Morrison VA, Guatelli JC, Brooks PA, Kauffman CA, Pachucki CT, Neuzil KM, Betts RF, Wright PF, Griffin MR, Brunell P, Soto NE, Marques AR, Keay SK, Goodman RP, Cotton DJ, Gnann JW Jr, Loutit J, Holodniy M, Keitel WA, Crawford GE, Yeh S-S, Lobo Z, Toney JF, Greenberg RN, Keller PM, Harbecke R, Hayward AR, Irwin MR, Kyriakides TC, Chan CY, Chan ISF, Wang WWB, Annunziato PW, Silber JL (2005) A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med 352:2271–2284PubMedCrossRefGoogle Scholar
  62. Panum PL, Petersen JJ (1940) Observations made during the epidemic of measles on the Faroe Islands in the year 1846. Delta Omega Society; distributed by the American Public Health Association, New YorkGoogle Scholar
  63. Pasko MT, Beam TR Jr (1990) Persistence of anti-HBs among health care personnel immunized with hepatitis B vaccine. Am J Public Health 80:590–593PubMedCrossRefGoogle Scholar
  64. Permar SR, Klumpp SA, Mansfield KG, Kim WK, Gorgone DA, Lifton MA, Williams KC, Schmitz JE, Reimann KA, Axthelm MK, Polack FP, Griffin DE, Letvin NL (2003) Role of CD8(+) lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 77:4396–4400PubMedCrossRefGoogle Scholar
  65. Permar SR, Klumpp SA, Mansfield KG, Carville AA, Gorgone DA, Lifton MA, Schmitz JE, Reimann KA, Polack FP, Griffin DE, Letvin NL (2004) Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys. J Infect Dis 190:998–1005PubMedCrossRefGoogle Scholar
  66. Platkov E, Shlyakhov E, Glick Y, Khalemsky S, Fischbein A (2003) Immunologic evaluation of hepatitis B vaccine application in hospital staff. Int J Occup Med Environ Health 16:249–253PubMedGoogle Scholar
  67. Plotkin SA (2008) Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 47:401–409PubMedCrossRefGoogle Scholar
  68. Priddy FH, Brown D, Kublin J, Monahan K, Wright DP, Lalezari J, Santiago S, Marmor M, Lally M, Novak RM, Brown SJ, Kulkarni P, Dubey SA, Kierstead LS, Casimiro DR, Mogg R, Dinubile MJ, Shiver JW, Leavitt RY, Robertson MN, Mehrotra DV, Quirk E (2008) Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adults. Clin Infect Dis 46:1769–1781PubMedCrossRefGoogle Scholar
  69. Qin L, Gilbert PB, Corey L, McElrath MJ, Self SG (2007) A framework for assessing immunological correlates of protection in vaccine trials. J Infect Dis 196:1304–1312PubMedCrossRefGoogle Scholar
  70. Querec TD, Akondy RS, Lee EK, Cao W, Nakaya HI, Teuwen D, Pirani A, Gernert K, Deng J, Marzolf B, Kennedy K, Wu H, Bennoune S, Oluoch H, Miller J, Vencio RZ, Mulligan M, Aderem A, Ahmed R, Pulendran B (2009) Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 10:116–125PubMedCrossRefGoogle Scholar
  71. Ratnam S, Gadag V, West R, Burris J, Oates E, Stead F, Bouilianne N (1995) Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol 33:811–815PubMedGoogle Scholar
  72. Rolland M, Gilbert P (2011) Evaluating immune correlates in HIV type 1 vaccine efficacy trials: what RV144 may provide. AIDS Res Hum Retroviruses 28:400–404PubMedCrossRefGoogle Scholar
  73. Roome AJ, Walsh SJ, Carter ML, Hadler JL (1993) Hepatitis B vaccine responsiveness in Connecticut public safety personnel. JAMA 270:2931–2934PubMedCrossRefGoogle Scholar
  74. Ross AH (1962) Modification of chicken pox in family contacts by administration of gamma globulin. N Engl J Med 267:369–376PubMedCrossRefGoogle Scholar
  75. Saberifiroozi M, Gholamzadeh S, Serati AR (2006) The long-term immunity among health care workers vaccinated against hepatitis B virus in a large referral hospital in southern Iran. Arch Iran Med 9:204–207PubMedGoogle Scholar
  76. Sadaoka K, Okamoto S, Gomi Y, Tanimoto T, Ishikawa T, Yoshikawa T, Asano Y, Yamanishi K, Mori Y (2008) Measurement of varicella-zoster virus (VZV)-specific cell-mediated immunity: comparison between VZV skin test and interferon-gamma enzyme-linked immunospot assay. J Infect Dis 198:1327–1333PubMedCrossRefGoogle Scholar
  77. Samb B, Aaby P, Whittle HC, Seck AM, Rahman S, Bennett J, Markowitz L, Simondon F (1995) Serologic status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Infect Dis J 14:203–209PubMedCrossRefGoogle Scholar
  78. Scheibel I (1955) The uses and results of active tetanus immunization. Bull World Health Organ 13:381–394PubMedGoogle Scholar
  79. Siber GR (1997) Methods for estimating serological correlates of protection. Dev Biol Stand 89:283–296PubMedGoogle Scholar
  80. Skendzel LP (1996) Rubella immunity. Defining the level of protective antibody. Am J Clin Pathol 106:170–174PubMedGoogle Scholar
  81. Smith JG, Liu X, Kaufhold RM, Clair J, Caulfield MJ (2001) Development and validation of a gamma interferon ELISPOT assay for quantitation of cellular immune responses to varicella-zoster virus. Clin Diagn Lab Immunol 8:871–879PubMedGoogle Scholar
  82. Sneath PA, Kerslake EG, Sruby F (1937) Tetanus immunity: resistance of guinea pigs to lethal spore doses induced by active and passive immunization. Am J Hyg 25:464–476Google Scholar
  83. Stevens DA, Merigan TC (1980) Zoster immune globulin prophylaxis of disseminated zoster in compromised hosts. A randomized trial. Arch Intern Med 140:52–54PubMedCrossRefGoogle Scholar
  84. Szmuness W, Stevens CE, Harley EJ, Zang EA, Oleszko WR, William DC, Sadovsky R, Morrison JM, Kellner A (1980) Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 303:833–841PubMedCrossRefGoogle Scholar
  85. Szmuness W, Stevens CE, Harley EJ, Zang EA, Alter HJ, Taylor PE, Devera A, Chen GT, Kellner A (1982) Hepatitis B vaccine in medical staff of hemodialysis units: efficacy and subtype cross-protection. N Engl J Med 307:1481–1486PubMedCrossRefGoogle Scholar
  86. Takahashi M, Otsuka T, Okuno Y, Asano Y, Yazaki T (1974) Live vaccine used to prevent the spread of varicella in children in hospital. Lancet 2:1288–1290PubMedCrossRefGoogle Scholar
  87. Takahashi M, Asano Y, Kamiya H, Baba K, Ozaki T, Otsuka T, Yamanishi K (2008) Development of varicella vaccine. J Infect Dis 197(Suppl 2):S41–S44PubMedCrossRefGoogle Scholar
  88. Thalhimer W (1936) The prophylactic and therapeutic value of convalescent serums in some of the acute infectious diseases. Ann Intern Med 10:373–378Google Scholar
  89. The RTS, S Clinical Trials Partnership (2011) First results of phase 3 trial of RTS, S/AS01 malaria vaccine in African children. N Engl J Med 365:1863–1875CrossRefGoogle Scholar
  90. Trautmann L, Sekaly RP (2011) Solving vaccine mysteries: a systems biology perspective. Nat Immunol 12:729–731PubMedCrossRefGoogle Scholar
  91. Valats JC, Tuaillon E, Funakoshi N, Hoa D, Brabet MC, Bollore K, Ducos J, Vendrell JP, Blanc P (2010) Investigation of memory B cell responses to hepatitis B surface antigen in health care workers considered as non-responders to vaccination. Vaccine 28:6411–6416PubMedCrossRefGoogle Scholar
  92. Van Damme P, Van Herck K (2007) A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis 5:79–84PubMedCrossRefGoogle Scholar
  93. Vryheid RE, Kane MA, Muller N, Schatz GC, Bezabeh S (2000) Infant and adolescent hepatitis B immunization up to 1999: a global overview. Vaccine 19:1026–1037PubMedCrossRefGoogle Scholar
  94. Wassilak SGF, Roper MH, Kretsinger K, Orenstein WA (2008) Tetanus toxoid. In: Plotkin SA, Orenstein WA, Offit PA (eds) Vaccines, 5th edn. Saunders/Elsevier, PhiladelphiaGoogle Scholar
  95. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC (2008) Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med 14:617–621PubMedCrossRefGoogle Scholar
  96. Watson B (2008) Humoral and cell-mediated immune responses in children and adults after 1 and 2 doses of varicella vaccine. J Infect Dis 197(Suppl 2):S143–S146PubMedCrossRefGoogle Scholar
  97. Weinberg A, Levin MJ (2010) VZV T cell-mediated immunity. Curr Top Microbiol Immunol 342:341–357PubMedCrossRefGoogle Scholar
  98. Whittle HC, Aaby P, Samb B, Jensen H, Bennet J, Simondon F (1999) Effect of subclinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 353:98–102PubMedCrossRefGoogle Scholar
  99. Wiedermann G, Ambrosch F, Andre FE, D’Hondt E, Delem A, Safary A (1992) Persistence of vaccine-induced antibody to hepatitis A virus. Vaccine 10(Suppl 1):S129–S131PubMedCrossRefGoogle Scholar
  100. Wolters KL, Dehmel H (1942) Final investigations into tetanus prevention by active immunization. Zeitschrift für hygiene und infektions krankheiten medizinische, mikrobiologie und viralogie 124:326–332Google Scholar
  101. Zaia JA, Levin MJ, Preblud SR, Leszczynski J, Wright GG, Ellis RJ, Curtis AC, Valerio MA, Legore J (1983) Evaluation of varicella-zoster immune globulin: protection of immunosuppressed children after household exposure to varicella. J Infect Dis 147:737–743PubMedCrossRefGoogle Scholar
  102. Zerboni L, Nader S, Aoki K, Arvin AM (1998) Analysis of the persistence of humoral and cellular immunity in children and adults immunized with varicella vaccine. J Infect Dis 177:1701–1704PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2012

Authors and Affiliations

  1. 1.Najít Technologies, IncBeavertonUSA

Personalised recommendations